NYSE:LCI Lannett (LCI) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free LCI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.65▼$2.5152-Week Range N/AVolume280,600 shsAverage Volume92,067 shsMarket Capitalization$7.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Lannett alerts: Email Address Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Lannett Stock (NYSE:LCI)Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Read More Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> LCI Stock News HeadlinesSeptember 20, 2023 | wsj.comLucky Core Industries Ltd.September 15, 2023 | thestreet.comLannett (LCI) Stock Sinks on Lowered Guidance, Canaccord DowngradeMarch 18, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:May 1, 2023 | finance.yahoo.comLannett Company, Inc. Enters Into Restructuring Support AgreementApril 20, 2023 | finance.yahoo.comNYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGSApril 4, 2023 | finance.yahoo.comLANNETT SHARES UPDATEFebruary 26, 2023 | thestreet.comWhy Lannett (LCI) Stock Is Down TodayFebruary 7, 2023 | finance.yahoo.comRecent uptick might appease Lannett Company, Inc. (NYSE:LCI) institutional owners after losing 26% over the past yearMarch 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.February 2, 2023 | finance.yahoo.comLannett Company, Inc. (NYSE:LCI) Q2 2023 Earnings Call TranscriptFebruary 1, 2023 | finance.yahoo.comLANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCEFebruary 1, 2023 | finance.yahoo.comLannett (LCI) Reports Q2 Loss, Tops Revenue EstimatesJanuary 25, 2023 | finance.yahoo.comLANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLITJanuary 25, 2023 | finance.yahoo.comLANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1January 4, 2023 | finance.yahoo.comLANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTSNovember 9, 2022 | finance.yahoo.comLannett Company First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsNovember 7, 2022 | finance.yahoo.comLANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAMNovember 2, 2022 | finance.yahoo.comLANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCEOctober 26, 2022 | finance.yahoo.comLANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2October 21, 2022 | finance.yahoo.comLANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANTOctober 19, 2022 | prnewswire.comLANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS - PR NewswireOctober 19, 2022 | finance.yahoo.comLANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGSOctober 15, 2022 | seekingalpha.comLCI Lannett Company, Inc.October 5, 2022 | finance.yahoo.comLannett Company, Inc. (LCI)September 28, 2022 | law360.comEx-Pharma CEO Denied 3rd Circ. Rehearing In $1M FBAR Case - Law360September 26, 2022 | forbes.comProbability Of Default Is Rising For High Yield Bonds And Leveraged Loans - ForbesSeptember 19, 2022 | bloomberg.comAdderall Shortages in US Spread to Two More Drug Suppliers - BloombergSee More Headlines Receive LCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lannett and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today3/18/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNYSE:LCI CUSIP51601210 CIK57725 Webwww.lannett.com Phone(215) 333-9000Fax215-333-9004Employees810Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($18.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-231,620,000.00 Net Margins-62.40% Pretax Margin-62.67% Return on EquityN/A Return on Assets-13.39% Debt Debt-to-Equity RatioN/A Current Ratio2.23 Quick Ratio1.39 Sales & Book Value Annual Sales$340.58 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($23.34) per share Price / BookN/AMiscellaneous Outstanding Shares10,770,000Free Float9,354,000Market Cap$7.38 million OptionableOptionable Beta0.95 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesTimothy C. CrewChief Executive Officer & DirectorJohn KozlowskiChief Financial Officer & Vice President-FinanceRobert EhlingerChief Information Officer & Vice PresidentMaureen M. CavanaughChief Commercial Operations Officer & Senior VPJohn M. AbtChief Quality Operations Officer & Vice PresidentKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXSoligenixNASDAQ:SNGXVaccinexNASDAQ:VCNXPasithea TherapeuticsNASDAQ:KTTACadrenal TherapeuticsNASDAQ:CVKDView All Competitors LCI Stock Analysis - Frequently Asked Questions How were Lannett's earnings last quarter? Lannett Company, Inc. (NYSE:LCI) released its quarterly earnings data on Wednesday, November, 3rd. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.00) by $0.08. The firm earned $101.53 million during the quarter, compared to analysts' expectations of $98.62 million. During the same period last year, the company posted $0.24 EPS. When did Lannett's stock split? Shares of Lannett reverse split on the morning of Tuesday, February 7th 2023. The 1-4 reverse split was announced on Tuesday, February 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What is Timothy Crew's approval rating as Lannett's CEO? 9 employees have rated Lannett Chief Executive Officer Timothy Crew on Glassdoor.com. Timothy Crew has an approval rating of 28% among the company's employees. This puts Timothy Crew in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lannett own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lannett investors own include Akorn (AKRX), Skechers U.S.A. (SKX), Integrated Device Technology (IDTI), Bank of America (BAC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Rite Aid (RAD) and NVIDIA (NVDA). This page (NYSE:LCI) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lannett Company, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.